Table 1.
Patient characteristics
| Variables | NDMM | RRMM* |
|---|---|---|
| Median age, years(range) | 56.5 (46–78) | |
| Sex (M/F) | 11/5 | |
| Durie-Salmon staging, n(%) | ||
| Stage IA | 1 (6.25%) | |
| Stage IB | - | |
| StageIIA | 1 (6.25%) | |
| StageIIB | - | |
| StageIIIA | 12 (75%) | |
| StageIIIB | 2 (12.5%) | |
| R-ISS, n(%) | ||
| Stage I | - | |
| Stage II | 14 (87.5%) | |
| Stage III | 2 (12.5%) | |
| Median Glb(g/L), (range) | 47.7 (17.3–95.3) | 25.5 (15.3–36.8) |
| ≥35 g/L | 9 (56.25%) | 1 (6.25%) |
| <35 g/L | 7 (43.75%) | 15 (93.75%) |
| Median β2-microglobulin (mg/L), (range) | 2.135 (1.041–14.4) | 2.2 (1.059–6.62) |
| ≥5.5 mg/L | 3 (18.75%) | 1 (6.25%) |
| <5.5 mg/L | 13 (81.25%) | 14 (87.5%) |
| Unknown | - | 1 (6.25%) |
| Median Hb (g/L), (range) | 107 (61–153) | 128 (77–179) |
| ≥105 g/L | 9 (56.25%) | 13 (81.25%) |
| <105 g/L | 7 (43.75%) | 3 (18.75%) |
| Median Cre (μmol/L), (range) | 78.5 (54–488) | 76 (49–578) |
| ≥176.8 μmol/L | 2 (12.5%) | 2 (12.5%) |
| <176.8 μmol/L | 14 (87.5%) | 14 (87.5%) |
| Median Ca (mmol/L), (range) | 2.295 (1.91–2.58) | 2.255 (1.91–2.42) |
| ≥2.65 mmol/L | - | - |
| <2.65 mmol/L | 16 (100%) | 16 (100%) |
| Median LDH (U/L), (range) | 194 (123–292) | 234.5 (166–477) |
| Normal | 14 (87.5%) | 8 (50%) |
| High | 1 (6.25%) | 6 (37.5%) |
| Unknown | 1 (6.25%) | 2 (12.5%) |
| M protein subtype, n (%) | ||
| IgG kappa | 3 (18.75%) | |
| IgG lambda | - | |
| IgA kappa | 2 (12.5%) | |
| IgA lambda | 2 (12.5%) | |
| IgD lambda | 2 (12.5%) | |
| Kappa light chain | 1 (6.25%) | |
| Lambda light chain | 6 (37.5%) | |
| Median Plasma cells in bone marrow (%), (range) | 28 (5–94.5) | 9.5 (0–71) |
| Median TTP, months (range) | 14.5 (6–46) |
Abbreviations: M: male, F: female, R-ISS: Revised International Staging System, Glb: globulin, Hb: hemoglobin, Cre: creatinine, Ca: calcium, LDH: lactate dehydrogenase, TTP:Time to progression.
* All patients received chemotherapy based on the bortezomib regimen.